X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AMAR REMEDIES with HYPERMARCAS SA - Brazil - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs HYPERMARCAS (Brazil) - Comparison Results

HYPERMARCAS (Brazil)
   Change

Hypermarcas SA is a leading consumer goods company in Brazil. The company is present in pharmaceuticals and personal care. The company's pharmaceuticals products include over-the-counter medications, generic drugs and prescription medications. The c... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AMAR REMEDIES   HYPERMARCAS
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
HYPERMARCAS
Dec-14
AMAR REMEDIES/
HYPERMARCAS
5-Yr Chart
Click to enlarge
High Rs164445-   
Low Rs86325-   
Sales per share (Unadj.) Rs261.6151.8-  
Earnings per share (Unadj.) Rs17.413.4-  
Cash flow per share (Unadj.) Rs22.316.9-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs100.7242.5-  
Shares outstanding (eoy) m26.16635.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.52.5 18.8%   
Avg P/E ratio x7.228.8 24.9%  
P/CF ratio (eoy) x5.622.8 24.6%  
Price / Book Value ratio x1.21.6 78.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m3,270244,615 1.3%   
No. of employees `000NA12.9 0.0%   
Total wages/salary Rs m1634,717 3.5%   
Avg. sales/employee Rs ThNM7,453.3-  
Avg. wages/employee Rs ThNM364.7-  
Avg. net profit/employee Rs ThNM656.1-  
INCOME DATA
Net Sales Rs m6,84496,408 7.1%  
Other income Rs m211,628 1.3%   
Total revenues Rs m6,86598,036 7.0%   
Gross profit Rs m1,13123,268 4.9%  
Depreciation Rs m1282,256 5.7%   
Interest Rs m39812,278 3.2%   
Profit before tax Rs m62610,362 6.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-206 24.3%   
Tax Rs m1211,669 7.3%   
Profit after tax Rs m4558,487 5.4%  
Gross profit margin %16.524.1 68.5%  
Effective tax rate %19.316.1 120.0%   
Net profit margin %6.68.8 75.5%  
BALANCE SHEET DATA
Current assets Rs m4,90499,395 4.9%   
Current liabilities Rs m3,58161,573 5.8%   
Net working cap to sales %19.339.2 49.3%  
Current ratio x1.41.6 84.8%  
Inventory Days Days12452 241.0%  
Debtors Days Days100121 82.6%  
Net fixed assets Rs m1,68934,340 4.9%   
Share capital Rs m262108,418 0.2%   
"Free" reserves Rs m2,3580-   
Net worth Rs m2,635154,006 1.7%   
Long term debt Rs m50763,324 0.8%   
Total assets Rs m6,862286,093 2.4%  
Interest coverage x2.61.8 139.5%   
Debt to equity ratio x0.20.4 46.8%  
Sales to assets ratio x1.00.3 296.0%   
Return on assets %12.47.3 171.3%  
Return on equity %17.35.5 313.3%  
Return on capital %31.010.3 300.3%  
Exports to sales %4.00-   
Imports to sales %00-   
Net fx Rs m2710-   
CASH FLOW
From Operations Rs m-31313,678 -2.3%  
From Investments Rs m-4891,405 -34.8%  
From Financial Activity Rs m769-1,261 -61.0%  
Net Cashflow Rs m-3313,825 -0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for HYPERMARCAS (Brazil) is Brazil Reais. All data has been converted at 20.6 Rs / BRL

Compare AMAR REMEDIES With: P&G (US)  UNILEVER PLC. (UK)  

Compare AMAR REMEDIES With: JYOTHY LABS  RELAXO FOOTWEARS  LINC PEN & PLASTICS LTD  GILLETTE INDIA  PIDILITE INDUSTRIES  



Today's Market

Sensex Down Over 120 Points; Realty Stocks Witness Losses(11:30 am)

After opening the day marginally higher, Indian share markets witnessed selling pressure and went on to trade on a negative note.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

The Recipe to Over 60% Returns in Less Than a Year(The 5 Minute Wrapup)

Sep 9, 2017

Short term crisis in some companies could unveil some great investing opportunities.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 8-QTR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS